Chimeric Therapeutics Limited TEMPASX: CHMDA

CHM CORE-NK Phase 1B clinical trial achieves 60% CR/CRi

· Issued by Chimeric Therapeutics Limited TEMP

Filed with ASX · · 3 pages · English

On 6ix: 6ix.com/news/chm-core-nk-phase-1b-clinical-trial-achieves-60percent-crcri

Chimeric Therapeutics Limited Temp has released a press release.

View Attachment

6ix is checking which company filed this.

Chimeric Therapeutics Limited TEMP on 6ix

Later from Chimeric Therapeutics Limited TEMP

All Chimeric Therapeutics Limited TEMP news releases